Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review
- PMID: 15769640
- DOI: 10.2741/1634
Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review
Abstract
The acquisition of multi-drug resistance (MDR) in cancer cells subjected to anticancer agents remains a formidable obstacle to successful therapeutic outcomes in cancer patients. As the name implies, the resistance phenotype (MDR) is not typically limited to the drug initially used to eradicate cancer but is often transferred to structurally unrelated chemotherapeutic agents. The mechanisms underlying the development of MDR have been extensively studied and are considered multifactorial. Interestingly, recent observations have shown that altered intracellular distribution of drugs may play an important role in the establishment of the MDR phenotype. Such intracellular redistribution events may reduce the opportunity for a drug molecule to permeate into a drug _target-containing compartment and thus limit its therapeutic effect. This review summarizes cases in which intracellular redistribution of drugs has been associated with the emergence of MDR in cancer cells. The review also provides a general overview regarding intracellular compartmentalization mechanisms of drugs in cells, which will include some of the known factors/conditions that influence the accumulation of drugs into specific cellular compartments. Finally, potential strategies for overcoming this resistance phenotype are discussed.
Similar articles
-
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.Curr Pharm Des. 2015;21(38):5589-604. doi: 10.2174/1381612821666151002113546. Curr Pharm Des. 2015. PMID: 26429711 Review.
-
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110. doi: 10.5414/cpp38094. Int J Clin Pharmacol Ther. 2000. PMID: 10739113 Review.
-
Molecular mechanisms of multidrug resistance in cancer chemotherapy.Pathol Res Pract. 1996 Jul;192(7):768-80. doi: 10.1016/S0344-0338(96)80099-9. Pathol Res Pract. 1996. PMID: 8880878 Review.
-
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.World J Gastroenterol. 2002 Aug;8(4):644-9. doi: 10.3748/wjg.v8.i4.644. World J Gastroenterol. 2002. PMID: 12174371 Free PMC article.
-
Multidrug resistance: can different keys open the same lock?Drug Resist Updat. 2002 Apr;5(2):61-4. doi: 10.1016/s1368-7646(02)00020-1. Drug Resist Updat. 2002. PMID: 12135581 Review.
Cited by
-
Progressive cancer _targeting by programmable aptamer-tethered nanostructures.MedComm (2020). 2024 Oct 20;5(11):e775. doi: 10.1002/mco2.775. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39434968 Free PMC article. Review.
-
Small molecule quercetin binds MALAT1 triplex and modulates its cellular function.Mol Ther Nucleic Acids. 2022 Sep 23;30:241-256. doi: 10.1016/j.omtn.2022.09.016. eCollection 2022 Dec 13. Mol Ther Nucleic Acids. 2022. PMID: 36284512 Free PMC article.
-
A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.Int J Med Sci. 2014 Mar 18;11(5):479-87. doi: 10.7150/ijms.8340. eCollection 2014. Int J Med Sci. 2014. PMID: 24688312 Free PMC article.
-
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.Sci Rep. 2015 Dec 4;5:17730. doi: 10.1038/srep17730. Sci Rep. 2015. PMID: 26635117 Free PMC article.
-
Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux.Front Oncol. 2021 Feb 1;10:614288. doi: 10.3389/fonc.2020.614288. eCollection 2020. Front Oncol. 2021. PMID: 33598432 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials